Docetaxel (DCT)
Docetaxel is a clinically well-established anti-mitotic chemotherapy medication. It is used mainly for the treatment of breast, ovarian, prostate, and non-small cell lung cancer. Docetaxel has an FDA approved claim for treatment of patients who have locally advanced, or metastatic breast or non small-cell lung cancer who have undergone anthracycline-based chemotherapy and failed to stop cancer progression or relapsed and a European approval for use in hormone-refractory prostate cancer. Docetaxel is of the chemotherapy drug class; taxane, and is a semi-synthetic analogue of paclitaxel (Taxol), an extract from the bark of the rare Pacific yew tree Taxus brevifolia. Docetaxel differs from paclitaxel at two positions in its chemical structure. It has a hydroxyl functional group on carbon 10, whereas paclitaxel has an acetate ester, and a tert-butyl carbamate ester exists on the phenylpropionate side chain instead of the benzyl amide in paclitaxel.

Organism species: Pan-species (General)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Complete Antigen of Docetaxel (DCT) Antigenic Transformation Customized Service Offer
Antibodies n/a Monoclonal Antibody to Docetaxel (DCT) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Docetaxel (DCT) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Docetaxel (DCT) CLIA Kit Customized Service Offer
n/a ELISA Kit for Docetaxel (DCT) ELISA Kit Customized Service Offer